Colleagues, After careful consideration, BTOG has sadly decided that BTOG 2021 will not go ahead in January 2021. We hope to be able to hold BTOG 2021 in Spring 2021 and our 20th Conference – BTOG 2022 is in the … Read More
The National Institute for Health and Care Excellence’s (NICE) latest impact report on lung cancer is now available on its website. The impact report brings together NICE recommendations and real-world data to highlight how implementing NICE guidance is making a … Read More
February 2020 By Dr Adam Januszewski, Higher Specialty Trainee in Medical Oncology and Honorary Clinical Fellow, Imperial College London On application to medical school, lifelong learning is what I signed up to. Although at that point I wasn’t entirely sure … Read More
February 2020 By Dr Antonia Field-Smith, Consultant in Palliative Medicine, West Middlesex University Hospital Despite all the recent successes with immunotherapy, I am well aware that lung cancer remains the most common cause of cancer death in the UK. The … Read More
February 2020 By Dr Helen McDill, Respiratory Registrar and Interventional Respiratory Fellow, Derriford Hospital, Plymouth NHS Trust What a fantastic 3 days at BTOG 2020 – I have returned back to work full of ideas and enthusiasm about how to … Read More
A new website, launched as part of the My Pleural Effusion Journey project, provides information for patients, carers and clinicians on malignant pleural effusions. My Pleural Effusion Journey was funded by the North West Lung Centre Charity, based at Wythenshawe … Read More
November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Combination Immunotherapy for NSCLC: Checkmate-227 Further results from the Checkmate-227 trial were presented at ESMO 2019. Checkmate-227 is a study with multiple treatment arms, which has released results at various stages … Read More
November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Osimertinib Overall Survival Results: FLAURA The overall survival (OS) date from the FLAURA study was presented at the Presidential Session of ESMO 2019, following publication of the Progression Free Survival (PFS) … Read More
October 2019 By Tom Newsom-Davis, BTOG Vice-Chair Treatment of RET-Fusion NSCLC: LIBRETTO-001 RET fusions are found in a number of different cancer and account for approximately 2% of NSCLC. Although rare, they are predominantly found in younger patients, non-smokers or … Read More
Registration is now open for the International Mesothelioma Interest Group meeting, iMig 2020, in Brisbane, Australia, 25th-28th March, 2020. The closing date for abstracts is 30th October and can be submitted online. The event will bring together over 500 delegates from … Read More